Integra LifeSciences Holdings 2026 Q2 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- Integra LifeSciences reported second quarter 2026 revenue of $419 million, representing 0.8% reported growth and 0.7% organic growth year over year.
- Adjusted earnings per share for the quarter were $0.56, a 24% increase compared to the prior year and above the high end of guidance, driven by improved operating execution and tariff favorability.
- Specialty surgery revenue was $309.3 million, up 1.7% reported and 1.6% organic, with global neurosurgery growing 1.9% organically.
- Tissue reconstruction revenue was $109.5 million, down 1.9% reported and 2% organic, with positive growth in Dermasorb and Primatrix offset by declines in Integra Skin and Micro Matrix year over year.
- Operating cash flow was $22.8 million in the quarter, up from $8.9 million prior year, with free cash flow of $10.5 million and a conversion rate of 24%.
- Net debt was $1.6 billion with a total leverage ratio of 4.1 times, down from 4.5 times at year end 2025, and liquidity totaled approximately $496 million.
- The company is on track to approach the upper end of its target leverage range of 2.5 to 3.5 times by the end of 2026.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Good day, and thank you for standing by. Welcome to the Integra LifeSciences second quarter 2026 financial results. At this time, all participants are in a listen-only mode. Please be advised that today's conference is being recorded. After the speaker's presentation, there will be a question and answer session. To ask a question, please press star one one on your telephone and wait for your name to be announced. To withdraw your question, please press star one one again. I would now like to hand the conference over to your speaker today, Chris Ward, Senior Director of Investor Relations.
Good morning, and thank you for joining the Integra LifeSciences second quarter 2026 earnings conference call. Joining me on the call are Stuart Essig, Chairman, President, and Chief Executive Officer, and Lea Knight, Chief Financial Officer. We issued a press release this morning announcing our second quarter 2026 financial results. The release and earnings presentation we reference during the call are available at integralife.com under Investors, Events and Presentations. Look for the file name Second Quarter 2026 Earnings Call Presentation. Before we begin, I want to remind you that many statements made during this call may be considered forward-looking. Factors that could cause actual results to differ materially are discussed in the company's Exchange Act reports filed with the SEC. These factors are also detailed in the release. Also in our prepared remarks, we'll reference reported and organic revenue growth.
Organic revenue growth excludes the effects of foreign currency, acquisitions, and divestitures. Unless otherwise stated, all disaggregated and franchise-level revenue growth rates are based on organic performance. Lastly, our comments today will include certain non-GAAP financial measures. Reconciliations of non-GAAP financial measures are included in today's press release, which is an exhibit to Integra's current report on Form 8-K filed today with the SEC. With that, I will now turn the call over to Stuart.
Thank you, Chris, and good morning to everyone on the line. We are encouraged by our second quarter results. We delivered on our commitments, achieved important milestones, and advanced our key priorities across the business. As a result, we are operating with greater consistency and strengthening our foundation for long-term growth. Revenue for the second quarter was $419 million, up $27 million sequentially, and in line with our May guidance. Adjusted earnings per share were above the high end of our guidance range, driven by our improved operating execution and favorable tariff dynamics in the quarter. We are reaffirming our full-year organic revenue growth outlook and adjusted EPS guidance as our underlying operating expectations for the year remain unchanged. We are updating our reported revenue outlook to reflect the impact of foreign exchange. Lea will provide additional color on our guidance.
Turning to our business segments, specialty surgery remains a core strength of the company. We hold the leading position in neurosurgery, supported by a broad portfolio of differentiated products, longstanding customer relationships, and clinical interventions that are deeply embedded in the daily practice of neurosurgeons. Importantly, our leading positions in neurosurgery and instruments provide unique access to hospitals, IDNs, and GPOs, strengthening our enterprise commercial footprint and offering further growth opportunities across our broader portfolio. ENT remains an important emerging growth opportunity for Integra. We continue to invest in the pipeline and are confident in our commercial team's ability to drive meaningful growth contributions as the business and portfolio continue to develop. Turning to tissue reconstruction, we maintain a strong market position anchored by Integra Skin, our flagship product and the market leader in dermal regeneration.
The franchise is built on the broadest product portfolio available, including Integra Skin, PriMatrix, AmnioExcel, MicroMatrix, and DuraSorb. This drives market leadership in complex wound reconstruction, particularly in the hospital setting. Looking more broadly at the market, we believe Integra LifeSciences is uniquely positioned within the evolving reimbursement landscape. The combination of the breadth of our portfolio, deep clinical evidence, a predominantly hospital-based business model, and pricing aligned with both hospital and outpatient reimbursement dynamics is difficult to replicate. As the market continues to adjust to the recent CMS reimbursement changes, we believe these strengths make us one of the best-positioned companies in wound reconstruction. We are also encouraged by the continued adoption of PriMatrix following its relaunch. Strong customer adoption reinforces our confidence in both the value of this product and our ability to successfully bring important products back to the market.
Building on that momentum, we have successfully restarted manufacturing at our Braintree facility, marking an important operational milestone for the company. We are now building inventory to support the commercial relaunch of SurgiMend 510(k) product in the fourth quarter. While the relaunch of SurgiMend represents an important near-term milestone, our broader objective is to expand the opportunity for both SurgiMend and DuraSorb through our dual PMA strategy in implant-based breast reconstruction. We are advancing toward an expanded label for SurgiMend, which we expect in 2027, with DuraSorb expected later that same year. Once approved, SurgiMend and DuraSorb would provide both biologic and synthetic solutions with the first two PMA indications for implant-based breast reconstruction, expanding surgeon choice and further strengthening one of Integra's key competitive advantages, the breadth of our portfolio.
Combined with our established presence in complex wound reconstruction and our commercial capabilities, we believe this strategy positions us well for long-term growth in this market. Beyond our portfolio initiatives, we have begun to realize the benefits of the broader changes we have made in how the company operates. By better aligning our commercial organization, operating model, and transformation initiatives around a common set of priorities, we are improving execution and enhancing coordination across the business. Together, these efforts are creating a more efficient organization and have contributed to cost savings in the second quarter. As we continue to improve supply reliability and operational performance, we see a clear path to further margin improvement in the coming years. That same focus on disciplined execution is reflected in our approach to capital allocation. Deleveraging continues to be our top priority.
We exited the second quarter of 2026 at 4.1 times total leverage, down from 4.5 times at year-end. We remain on track to approach the upper end of our target leverage range by the end of 2026. Overall, we are advancing important milestones, improving how we operate, and strengthening the foundation for sustainable growth. We remain focused on creating long-term value for customers, shareholders, and employees. With that, let me turn the call over to Lea for additional detail on our results and outlook.
Thank you, Stuart. Good morning, everyone. I want to begin by thanking our team for their continued strong execution in the second quarter. Turning to slide five, I will cover our second quarter financial results. Our second quarter revenues were $419 million, representing 0.8% growth on a reported basis and 0.7% growth on an organic basis. These results build on the progress we have made over the past year, and they reflect the steadier, more predictable performance we are now delivering quarter to quarter. Adjusted EPS for the quarter was $0.56, an increase of 24% compared to the prior year. Relative to our May guidance, revenue delivery and transformation savings were in line with our expectations, and stronger overall operational execution drove performance to the high end of our guidance range.
In addition, we benefited from $0.05 per share of tariff favorability versus our May guidance, which contributed to our adjusted EPS performance above the high end of our guidance range. Gross margin for the quarter was 61.3%, up approximately 60 basis points from 60.7% in the prior year, reflecting efficiencies achieved across manufacturing operations and lower remediation spending. Adjusted EBITDA margin was 18.7%, up approximately 160 basis points versus 17.1% in Q2 2025, reflecting the benefits of the gross margin drivers I just discussed, together with contributions from our recent margin improvement initiatives. Cash flows from operations totaled $22.8 million in the second quarter, and capital expenditures were $12.3 million. Turning to slide six, we will take a deeper dive into our Specialty Surgery's revenue highlights for the second quarter. Specialty Surgery revenue was $309.3 million, representing 1.7% growth on a reported basis.
On an organic basis, revenue grew 1.6% compared to the prior year. Global Neurosurgery delivered 1.9% organic growth, driven by Certas Plus, CUSA, and Bactiseal, as supply reliability and fulfillment have continued to improve. Sales of capital equipment were down approximately 1%, as double-digit growth in CUSA was offset by a decline in smaller-ticket capital equipment during the period. We remain confident in the hospital capital environment and maintain a positive outlook for capital for the year. Instruments grew low single digits, benefiting from order timing relative to the first quarter. We continue to expect growth for the full year. In ENT, revenue declined low single digits, reflecting continued growth in MicroFrance ENT instruments, offset by ongoing pressures in sinus balloons. Revenue in our international markets grew low single digits as improving supply is strengthening our ability to meet customer demand. Moving to our Tissue Reconstruction segment on slide seven.
Tissue Reconstruction revenues were $109.5 million, down 1.9% on a reported basis and down 2% on an organic basis compared to the prior year. Within wound reconstruction, we continue to see positive growth contributions from DuraSorb and encouraging momentum following the relaunch of PriMatrix. While Integra Skin grew sequentially over the first quarter, it was down year-over-year as the second quarter of 2025 benefited from a significant backorder clearance for the product. MicroMatrix also declined in the quarter versus the prior year. For the first half of the year, Wound Reconstruction was approximately flat versus 2025, and its performance remains within the range of outcomes contemplated in our full-year guidance. During the second quarter, private label sales grew 4.7%. Finally, international sales and Tissue Reconstruction grew low single digits, driven by Integra Skin.
If you turn to slide eight, I will provide a brief update on our balance sheet, capital structure, and cash flow. Operating cash flow for the second quarter was $22.8 million, compared to $8.9 million in the prior year. Our second quarter operating cash flow also reflects an $11 million final milestone payment related to the Sia acquisition. For the first half of 2026, operating cash flow increased $35 million compared to 2025, and we remain on track to deliver an approximate $150 million improvement in operating cash flow for the year, driven by EBITDA growth, working capital efficiency and an approximate $60 million reduction in cash expenditures related to EU MDR compliance and Braintree startup costs. Free cash flow for the quarter was $10.5 million, with a free cash flow conversion rate of 24%.
As of June 30th, net debt was $1.6 billion and our consolidated total leverage ratio was 4.1 times within our current maximum allowable leverage of 5 times. Reducing our leverage and continued debt repayment remain our top capital allocation priorities for 2026. We will continue to reduce our leverage over the course of the year and expect to approach the upper end of our target leverage range of 2.5-3.5 times by the end of 2026. The company had total liquidity of approximately $496 million, including approximately $274 million in cash and short-term investments, with the remainder available under our revolving credit facility. Turning to slide nine, I will provide our consolidated revenue and adjusted earnings per share guidance for the third quarter and full-year 2026.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
12 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
